Our research activity focuses on the development of advanced molecular diagnostics technologies and point-of-care devices for early detection and management of diseases. Our highly multidisciplinary research activities combines the fundamental and translational studies at the interface between chemistry, physics, nanotechnology, and biology.
138
Publications
$6.9M
Total Funding
4200
Citation Count
387
Verified Review
Latest Research
Nanomachineries for Exosomes and Exosomal Biomarkers Analysis

The Shiddiky Laboratory is pursuing studies of the development of multifunctional magnetic nanomaterials based novel nanomachineries for the highly selective isolation and sensitive detection of exosome and exosomal biomarkers in patients with cancer and other diseases.

Read More About Nanomachineries

Nanomachineries for Exosomes and Exosomal Biomarkers Analysis
‘Metal-Biomolecules’ Affinity Interaction for Genetic, Epigenetic, and Proteomic Biomarkers

A novel platform method based on metal-biomolecules affinity interaction (i.e., adsorption) for the analysis of a range of genetic, epigenetic, and proteomic biomarkers in patients with cancers and other diseases. This method can overcome the major technological drawbacks in current biosensing approaches.

Read More About Nanobiosensing

‘Metal-Biomolecules’ Affinity Interaction for Genetic, Epigenetic, and Proteomic Biomarkers
Twitter Feed

We are glad to hear that our article on exosomes is one of the top downloaded papers in Small and received over 120 citations in 1.5 year. @cfsalomo @N_T_Nguyen @Griffith_Uni @AdvSciNews @Wiley_Chemistry @WileyGlobal @wileysmall @Griffith_Uni
https://onlinelibrary-wiley-com.libraryproxy.griffith.edu.au/doi/abs/10.1002/smll.201702153

@NobelPrize 1987 Japanese scientists find a strange type of DNA in E.Coli. In 2002, Rudd Jansen calls the DNA, CRISPR and the enzyme involved Cas9. In 2007 Danish scientists explain how CRISPR works. In 2012 Jennifer Doudna & Emmanuelle Charpentier, show CRISPR-Cas9 can be used to edit genes

Load More...